Chronic, recurrent Lymphocytic Leukemia Recruiting Phase 2 Trials for Venetoclax (DB11581)

Also known as: Recurrent Chronic Lymphocytic Leukemia

IndicationStatusPhase
DBCOND0112002 (Chronic, recurrent Lymphocytic Leukemia)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02846623Atezolizumab, Obinutuzumab, and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Relapsed or Refractory Richter SyndromeTreatment